Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews · Musculoskeletal

No studies found 4 · 57.1%GRADE not reported 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 3 · 42.9%High 0 · 0%

Back pain · Patients with ankylosing spondylitis

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
no estimate extracted
6 studies · 454 participants
Moderate

Disease activity · Patients with ankylosing spondylitis

The review found no eligible studies for this question.

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mean improvement in Bath ankylosing spondylitis function index (BASFI) ‐ not reported · Patients with ankylosing spondylitis

The review found no eligible studies for this question.

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Mean improvement in Bath ankylosing spondylitis metrology index (BASMI) ‐ not reported · Patients with ankylosing spondylitis

The review found no eligible studies for this question.

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Radiographic progress ‐ not reported · Patients with ankylosing spondylitis

The review found no eligible studies for this question.

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Withdrawals due to adverse events · Patients with ankylosing spondylitis

Sulfasalazine probably leads to higher total number of withdrawals due to adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
RR 1.43 [1.04, 1.94]
11 studies · 895 participants
Moderate

Serious adverse events · Patients with ankylosing spondylitis

Sulfasalazine showed no clear difference in serious adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Sulfasalazine for ankylosing spondylitis 2014 · Cochrane Headline outcomes only
OR 7.5 [0.15, 378.16]
1 study · 264 participants
Moderate